BASKING RIDGE, N.J., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”),
a cell therapy company combining an industry-leading development and manufacturing services provider (PCT) with a select
therapeutic development pipeline, announces today that the Company will release financial results for the second quarter of 2016
after the U.S. financial markets close on Tuesday, August 9, 2016.
Caladrius’ management will host a conference call for the investment community beginning at 5:00 pm ET on Tuesday, August 9,
2016, to discuss the financial results, provide a company update and answer questions.
Shareholders and other interested parties may participate in the conference call by dialing 877-562-4460 (U.S.) or 513-438-4106
(international) and providing conference ID 95709219. The call will also be broadcast live on the Internet via the Company’s
website at www.caladrius.com/events. The webcast will be archived on the Company’s website for 90 days.
About Caladrius Biosciences
Caladrius Biosciences, Inc., through its subsidiary, PCT, is a leading development and manufacturing partner to the cell therapy
industry. PCT works with its clients to overcome the fundamental challenges of cell therapy manufacturing by providing a wide
range of innovative services including product and process development, GMP manufacturing, engineering and automation, cell and
tissue processing, logistics, storage and distribution, as well as expert consulting and regulatory support. PCT and Hitachi
Chemical Co., Ltd. have entered into a strategic global collaboration to accelerate the creation of a global commercial cell
therapy development and manufacturing enterprise with deep engineering expertise. Around the core expertise of PCT, Caladrius
strategically develops select product candidates, which currently includes an innovative therapy for type 1 diabetes based on a
proprietary platform technology for immunomodulation. For more information, visit www.caladrius.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain
risks and uncertainties. All statements other than statements of historical fact contained in this press release are
forward-looking statements. The Company’s actual results could differ materially from those anticipated in these forward-looking
statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or
those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K
filed with the Securities and Exchange Commission (“SEC”) on March 15, 2016, and in the Company’s other periodic filings with the
SEC. The Company’s further development is highly dependent on, among other things, future medical and research developments and
market acceptance, which are outside of its control.
CONTACTS: Investors: LHA Investor Relations Anne Marie Fields Senior Vice President Phone: +1-212-838-8377 Email: afields@lhai.com Media: Caladrius Biosciences, Inc. Eric Powers Director, Communications and Marketing Phone: +1-212-584-4173 Email: epowers@caladrius.com
